Journal
DRUG DISCOVERY TODAY
Volume 15, Issue 15-16, Pages 622-629Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.06.011
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R01 HL052233, R01 HL080187, P01 HL048743, R01 HL070274] Funding Source: Medline
- NIDDK NIH HHS [R01 DK062729, R01 DK085006] Funding Source: Medline
- NINDS NIH HHS [R01 NS070001, P01 NS010828] Funding Source: Medline
Ask authors/readers for more resources
The Rho/rho-kinase (ROCK) pathway has an important role in the pathogenesis of several cardiovascular diseases. The activation of ROCK is involved in the regulation of vascular tone, endothelial dysfunction, inflammation and remodeling. The inhibition of ROCK has a beneficial effect in a variety of cardiovascular disorders. Evidence from animal models and from clinical use of ROCK inhibitors, such as Y-27632, fasudil and statins (i.e. pleiotropic effects), supports the hypothesis that ROCK is a potential therapeutic target. This review provides a current understanding of the role of ROCK pathway in the regulation of vascular function and the use of ROCK inhibitors in the treatment of cardiovascular disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
